Molecular Testing Lends Knowledge to Mutation Profile in Patients with Colorectal Cancer
December 10, 2019
Molecular testing provided the clinical data and mutation profile of Chinese patients with colorectal cancer in this retrospective study.
Hannah Slater
Tanya Siddiqi, MD, Discusses the TRANSCEND CLL-004 Trial
December 6, 2019
Tanya Siddiqi, MD, discussed the CAR T-cell trial ahead of the ASH Annual Meeting & Exposition in an interview with CancerNetwork®.
FDA Approves FoundationOne CDx as Companion Diagnostic for Alpelisib
December 5, 2019
The FDA approved FoundationOne CDx as a companion diagnostic for alpelisib in combination with fulvestrant for the treatment of men and postmenopausal women with HR+/HER2- PIK3CA-mutated breast cancer.
Chemical Straighteners and Permanent Hair Dyes May Increase Breast Cancer Risk
December 5, 2019
Research suggests that there is an association between breast cancer risk and the use of chemical straighteners and permanent hair dyes.
Phase I/II Studies of Annamycin in Acute Myeloid Leukemia Report Positive Interim Results
December 4, 2019
Additional positive interim safety and efficacy data were reported for annamycin in the treatment of patients with relapsed or refractory acute myeloid leukemia.
Patients with Invasive Secondary Breast Cancer May Have Higher Mortality
December 3, 2019
Patients who previously received radiotherapy for ductal carcinoma in situ may have higher mortality after developing an invasive second breast cancer.
Patients with Endometrial Cancer Pose High Risk of Dying from Cardiovascular Disease
December 2, 2019
Patients with endometrial cancer pose a very high risk of dying from cardiovascular diseases in the year after diagnosis, suggesting the necessity of early involvement of cardiologists for these patients.
FDA Grants Priority Review to Pembrolizumab for Non-Muscle Invasive Bladder Cancer
December 2, 2019
The FDA has granted priority review to a supplemental biologics license application for pembrolizumab for the treatment of patients with BCG-unresponsive, high-risk, non-muscle invasive bladder cancer.
Perioperative Study of Vorasidenib Shows Promise for Patients with Low-Grade Glioma
November 27, 2019
A perioperative study confirmed brain penetrance and robust biomarker suppression in patients with low-grade glioma with an IDH1 mutation.
Phase III HLX02 Study Meets Primary End Point in Patients with HER2+ Breast Cancer
November 26, 2019
Henlius announced that their multicenter phase III study met its primary end point of best overall response rate at week 24.
